Skip to main content

Table 3 Univariate and multivariate Cox-regression analysis of clinical factors associated with the occurrence of KDIGO 3 acute kidney injury

From: Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study

 

Univariate analysis

Multivariate analysis

OR (95% CI)

P-value

aOR (95% CI)a

P-value

Age

0.99 (0.97–1.01)

0.236

0.99 (0.96–1.02)

0.463

Sex

 

Female

1.00

1.00

Male

0.72 (0.38–1.36)

0.312

0.70 (0.34–1.46)

0.346

Baseline eGFR < 30

1.65 (0.69–3.91)

0.260

1.41 (0.48–4.14)

0.536

Diabetes

0.93 (0.47–1.82)

0.824

1.16 (0.56–2.41)

0.681

APACHII ≥ 25

0.64 (0.34–1.20)

0.162

0.53 (0.24–1.17)

0.118

Albumin ≤ 3 g/dL

0.81 (0.42–1.54)

0.522

0.66 (0.34–1.28)

0.221

CRAB

0.61 (0.29–1.29)

0.197

0.53 (0.24–1.17)

0.118

Aminoglycoside

1.01 (0.40–2.58)

0.982

0.99 (0.34–2.86)

0.979

Vancomycin

1.99 (0.92–4.3)

0.082

1.59 (0.65–3.89)

0.310

Intravenous contrast

1.07 (0.51–2.23)

0.865

0.89 (0.37–2.12)

0.785

Septic shockb

2.79 (1.51–5.16)

0.001

2.17 (1.10–4.26)

0.025

Daily colistin > 10 MIU

1.75 (0.94–3.26)

0.077

1.32 (0.61–2.83)

0.482

Colistin treatment duration

0.98 (0.92–1.03)

0.411

0.99 (0.93–1.04)

0.617

Inappropriate colistin dosage

2.29 (1.09–4.80)

0.028

2.52 (1.00–6.33)

0.049

Colistin formulation

 

Locolin®

1.00

1.00

Colimycin®

0.42 (0.22–0.82)

0.011

0.37 (0.18–0.77)

0.008

  1. aAdjusted odds ratio (aOR) and 95%CI were derived from cox regression analysis
  2. bPresent on the day of sample collection